Solventum (NYSE:SOLV) Sets New 12-Month High After Better-Than-Expected Earnings

Solventum Corporation (NYSE:SOLV) reached a new 52-week high during trading on Thursday following a better than expected earnings announcement. The company traded as high as $90.00 and last traded at $85.2360, with a volume of 103667 shares changing hands. The stock had previously closed at $87.47.

The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly results exceeded expectations. Solventum reported second-quarter adjusted earnings of $2.55 per share, well above the $1.91 analyst consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion, topping the $2.15 billion estimate, while reported sales rose 2.2% and organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised. Solventum increased its fiscal 2026 adjusted EPS outlook to $7.10-$7.20, above the roughly $6.55-$6.58 analyst expectation, while also raising its outlook for organic sales growth and free cash flow. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: The HIS separation could unlock value. Management said it intends to separate its healthcare software business, allowing Solventum to focus on MedTech while giving HIS greater flexibility to pursue investment and growth as a standalone company. Solventum Announces Intent to Separate its Health Information Systems Business
• Negative Sentiment: Investors may be concerned about separation and execution risks. The HIS transaction, reportedly influenced by activist pressure, adds restructuring complexity and uncertainty over timing, costs, stranded expenses and the eventual value of the separated businesses. Solventum to hive off healthcare software business, raises profit forecast

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on SOLV shares. Stifel Nicolaus lowered their price objective on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. BTIG Research lifted their target price on Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday. UBS Group restated a “buy” rating and issued a $101.00 price target on shares of Solventum in a research note on Thursday. Wells Fargo & Company reduced their price objective on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Finally, Mizuho set a $113.00 target price on shares of Solventum in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Solventum has a consensus rating of “Hold” and an average target price of $88.91.

Institutional Investors Weigh In On Solventum

Several large investors have recently bought and sold shares of the business. Independent Franchise Partners LLP increased its position in Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after acquiring an additional 2,456,451 shares during the last quarter. Norges Bank purchased a new position in shares of Solventum during the fourth quarter valued at approximately $147,467,000. Diamond Hill Capital Management Inc. grew its stake in shares of Solventum by 152.2% during the fourth quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after buying an additional 1,272,921 shares during the last quarter. Boston Partners grew its stake in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Solventum by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock worth $362,375,000 after buying an additional 763,308 shares during the period.

Solventum Stock Performance

The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The stock has a market capitalization of $14.62 billion, a PE ratio of 10.35, a P/E/G ratio of 1.36 and a beta of 0.60. The firm has a fifty day moving average price of $79.09 and a two-hundred day moving average price of $74.36.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.